Bevezetés: A pertussis (szamárköhögés) akut légúti fertőző betegség, amelyet a Bordetella pertussis okoz, és krónikus, súlyos köhögés jellemez. A pertussis védőoltás beadásának optimális rendje nem tisztázott, így országonként eltér. Célkitűzés: A pertussis szeroprevalenciájának becslése magyarországi felnőttek körében. Módszer: Szérum-antipertussistoxin-immunglobulin-G (anti-PT-IgG)-antitest-szintek elemzése enzimhez kötött immunoszorbens vizsgálattal felnőttekben, háziorvosi praxisokban, egy éven át. A szérumminták a gyártó utasításainak megfelelően kerültek osztályozásra, úgymint: erősen valószínűsíthető a fennálló/közelmúltban lezajlott fertőzés (≥1,5 optikaisűrűség [OS]-egység); valószínű a fennálló/közelmúltban lezajlott fertőzés (≥1,0 OS-egység); szeropozitivitás (>0,3 OS-egység); illetve szeronegativitás (≤0,3 OS-egység). Eredmények: A vizsgálatban 1999 felnőtt (60,6% nő; átlagos életkor 47,4 ± 17,7 év) vett részt. Közülük 14,8% volt szeropozitív, 1,1% esetében valószínűsíthető, míg 0,1% esetében erősen valószínűsíthető volt a fennálló/közelmúltban lezajlott fertőzés. Következtetések: A résztvevők 85,2%-a szeronegatív volt, és ily módon fogékony a pertussisfertőzésre. Körülbelül 1% esetében volt valószínűsíthető a fennálló/közelmúltban lezajlott fertőzés, amely potenciálisan átterjedhet fiatal csecsemőkre. A felnőttek immunizálása kulcsjelentőségű a csecsemők közvetett védelme szempontjából. Orv Hetil. 2018; 159(13): 503–510.
Pertussis. European Centre for Disease Prevention and Control (ECDC). Solna, 2016. Available from: http://ecdc.europa.eu/en/healthtopics/pertussis/Pages/index.aspx [accessed: June 22, 2016].
Torre JA, Benevides GN, de Melo AM, et al. Pertussis: the resurgence of a public health threat. Autops Case Rep. 2015; 5: 9–16.
Joo I. Epidemiology of pertussis in Hungary. Dev Biol Stand. 1991; 73: 357–359.
Heininger U, Andre P, Chlibek R, et al. Comparative epidemiologic characteristics of pertussis in 10 Central and Eastern European countries, 2000–2013. PLoS ONE 2016; 11: e0155949.
Vaccine Scheduler. Immunisation schedules by target disease pertussis in [Hungary]. European Centre for Disease Prevention and Control (ECDC). Solna, 2016. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx [accessed: June 22, 2016].
National Epidemiology Center. Vaccinations performance of 2015. [Országos Epidemiológiai Központ. Védőoltások teljesítése, 2015.] Epinfo 2016; 23: 369–381. Available from: http://www.oek.hu/oekfile.pl?fid=6840 [accessed: September 8, 2016]. [Hungarian]
Esposito S, Principi N, European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Vaccine Study Group (EVASG). Immunization against pertussis in adolescents and adults. Clin Microbiol Infect. 2016; 22(Suppl 5): S89–S95.
Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005; 24(Suppl 5): S58–S61.
Zepp F, Heininger U, Mertsola J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis. 2011; 11: 557–570.
World Health Organization (WHO). Pertussis vaccines: WHO position paper, August 2015 – Recommendations. Vaccine 2016; 34: 1423–1425.
Recommended immunisations for pertussis [All EU countries]. European Centre for Disease Prevention and Control (ECDC). Solna, 2016. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx [accessed: July 19, 2016].
European Centre for Disease Prevention and Control (ECDC). Expert consultation on pertussis 2012. Available from: http://ecdc.europa.eu/en/publications/Publications/pertussis-meeting-2012.pdf [accessed: June 22, 2016].
Surveillance Atlas of Infectious Diseases. European Centre for Disease Prevention and Control (ECDC). Solna, 2016. Available from: http://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=38&Indicator=106761&GeoResolution=2&TimeResolution=Year&StartTime=2006&EndTime=2014&CurrentTime=2014&Distribution=106765&DistributionRepresentation=B&TimeSeries=106761&TimeSeriesRepresentation=T&FixDataset=1 [accessed: June 22, 2016].
National Epidemiology Center. Data on infectious diseases. [Országos Epidemiológiai Központ. Fertőző betegségek adatai.] Epinfo 2016; 22: 640–650. Available from: http://www.oek.hu/oekfile.pl?fid=6451 [accessed: September 5, 2016]. [Hungarian]
Population Pyramids of the World from 1950 to 2100. Hungary 2015. Available from: http://populationpyramid.net/hungary/2015/ [accessed: September 8, 2016].
Barkoff AM, Gröndahl-Yli-Hannuksela K, He Q. Seroprevalence studies of pertussis: what have we learned from different immunized populations. Pathog Dis. 2015; 73: ftv050.
Cutts FT, Hanson M. Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countries. Trop Med Int Health 2016; 21: 1086–1098.
Taranger J, Trollfors B, Lagergård T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis. 2000; 181: 1010–1013.
Euro Diagnostica. Instruction: PERTUSSCAN PT IgG: ELISA for detection of IgG against Bordatella pertussis toxin (PT) in serum. Euro Diagnostica, Lundavägen, Malmö, Sweden, 2013 Oct. 120 p. Document No. E-23-0207-02.
Rendi-Wagner P, Tobias J, Moerman L, et al. The seroepidemiology of Bordetella pertussis in Israel – Estimate of incidence of infection. Vaccine 2010; 28: 3285–3290.
Pavlopoulou ID, Syriopoulou V, Daikos GL, et al. Pertussis seroprevalence in different age groups in Greece. Scand J Infect Dis. 2007; 39: 14–18.
Scott S, van der Sande M, Faye-Joof T, et al. Seroprevalence of pertussis in The Gambia: evidence for continued circulation of Bordetella pertussis despite high vaccination rates. Pediatr Infect Dis J. 2015; 34: 333–338.
Lee SY, Han SB, Bae EY, et al. Pertussis seroprevalence in Korean adolescents and adults using anti-pertussis toxin immunoglobulin G. J Korean Med Sci. 2014; 29: 652–656.
Conde-Glez C, Lazcano-Ponce E, Rojas R, et al. Seroprevalence of Bordetella pertussis in the Mexican population: a cross-sectional study. Epidemiol Infect. 2014; 142: 706–713.
Wanlapakorn N, Ngaovithunvong V, Thongmee T, et al. Seroprevalence of antibodies to pertussis toxin among different age groups in Thailand after 37 years of universal whole-cell pertussis vaccination. PLoS ONE 2016; 11: e0148338.
González-Escalada A, García-García L, Viguera-Ester P, et al. Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, and B. pertussis in young adults of Madrid, Spain. Hum Vaccin Immunother. 2013; 9: 1918–1925.
Palazzo R, Carollo M, Fedele G, et al. Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012–2013). J Med Microbiol. 2016; 65: 649–657.
Wirsing von König CH. Pertussis diagnostics: overview and impact of immunization. Expert Rev Vaccines 2014; 13; 1167–1174.
Recommended adult immunization schedule for adults aged 19 years or older, by vaccine and age group. United States, 2016. Centers for Disease Control and Prevention (CDC), 2016. Available from: http://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html [accessed: July 20, 2016].
Caboré RN, Piérard D, Huygen K. A Belgian serosurveillance/seroprevalence study of diphtheria, tetanus and pertussis using a luminex xMAP technology-based pentaplex. Vaccines (Basel) 2016; 4: E16.
de Greeff SC, de Melker HE, van Gageldonk PG, et al. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS ONE 2010; 5: e14183.
Huygen K, Rodeghiero C, Govaerts D, et al. Bordetella pertussis seroprevalence in Belgian adults aged 20–39 years, 2012. Epidemiol Infect. 2014; 142: 724–728.
Launay O, Toneatti C, Bernede C, et al. Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccin. 2009; 5: 341–346.
Rønn PF, Dalby T, Simonsen J, et al. Seroepidemiology of pertussis in a cross-sectional study of an adult general population in Denmark. Epidemiol Infect. 2014; 142: 729–737.
Xu Y, Wang L, Xu J, et al. Seroprevalence of pertussis in China: need to improve vaccination strategies. Hum Vaccin Immunother. 2014; 10: 192–198.
Chen Z, Zhang J, Cao L, et al. Seroprevalence of pertussis among adults in China where whole cell vaccines have been used for 50 years. J Infect. 2016; 73: 38–44.
de Melker HE, Versteegh FG, Schellekens JF, et al. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect. 2006; 53: 106–113.
Carcione D, Regan AK, Tracey L, et al. The impact of parental postpartum pertussis vaccination on infection in infants: A population-based study of cocooning in Western Australia. Vaccine 2015; 33: 5654–5661.
Healy CM, Rench MA, Wootton SH, et al. Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. Pediatr Infect Dis J. 2015; 34: 22–26.
Safadi MA. Control of pertussis in infants: time has finally come? Expert Rev. Vaccines 2015; 14: 781–783.
McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics 2015; 135: 331–343.
Mertsola J, Van Der Meeren O, He Q, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular partussis vaccine in young adults. Clin Infect Dis. 2010; 51: 656–662.
Ridda I, Yin JK, King C, et al. The importance of pertussis in older adults: a growing case for reviewing vaccination strategy in the elderly. Vaccine 2012; 30: 6745–6752.
El Ahmer OR, Essery SD, Saadi AT, et al. The effect of cigarette smoke on adherence of respiratory pathogens to buccal epithelial cells. FEMS Immunol Med Microbiol. 1999; 23: 27–36.
Torzsa P, Devadiga R, Tafalla M. Seroprevalence of Bordetella pertussis antibodies in adults in Hungary: results of an epidemiological cross-sectional study. BMC Infect Dis. 2017; 17: 242.